<!DOCTYPE html>
<html lang="de">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cholesterin-/Steroid-Biosynthese - Teil 2B</title>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');
        
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        :root {
            --primary-color: #8b5cf6;
            --secondary-color: #ec4899;
            --accent-color: #06b6d4;
            --success-color: #10b981;
            --warning-color: #f59e0b;
            --danger-color: #ef4444;
            --info-color: #3b82f6;
            --text-primary: #1f2937;
            --text-secondary: #4b5563;
            --text-muted: #6b7280;
            --bg-white: #ffffff;
            --bg-light: #f8fafc;
            --bg-lighter: #f1f5f9;
            --border-radius: 16px;
            --border-radius-lg: 24px;
            --spacing-xs: 8px;
            --spacing-sm: 16px;
            --spacing-md: 24px;
            --spacing-lg: 32px;
            --spacing-xl: 48px;
            --shadow-sm: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
            --shadow-md: 0 10px 15px -3px rgba(0, 0, 0, 0.1);
            --shadow-lg: 0 20px 25px -5px rgba(0, 0, 0, 0.1);
        }
        
        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            line-height: 1.6;
            color: var(--text-primary);
            background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
            min-height: 100vh;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: var(--spacing-md);
        }
        
        /* Header */
        .header {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
        }
        
        .header h1 {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color), var(--accent-color));
            background-size: 200% 200%;
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: clamp(2rem, 5vw, 3.5rem);
            font-weight: 700;
            margin-bottom: var(--spacing-sm);
            animation: gradientShift 4s ease-in-out infinite;
        }
        
        @keyframes gradientShift {
            0%, 100% { background-position: 0% 50%; }
            50% { background-position: 100% 50%; }
        }
        
        .header p {
            color: var(--text-secondary);
            font-size: 1.3rem;
            font-weight: 400;
        }
        
        /* Progress bar */
        .progress-container {
            background: var(--bg-lighter);
            border-radius: 50px;
            height: 10px;
            margin-top: var(--spacing-md);
            overflow: hidden;
        }
        
        .progress-fill {
            background: linear-gradient(90deg, var(--primary-color), var(--accent-color));
            height: 100%;
            border-radius: 50px;
            transition: width 0.8s cubic-bezier(0.4, 0, 0.2, 1);
            position: relative;
            overflow: hidden;
        }
        
        .progress-fill::after {
            content: '';
            position: absolute;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            background: linear-gradient(90deg, transparent, rgba(255, 255, 255, 0.3), transparent);
            animation: progressShimmer 2s infinite;
        }
        
        @keyframes progressShimmer {
            0% { transform: translateX(-100%); }
            100% { transform: translateX(100%); }
        }
        
        /* Navigation */
        .navigation {
            background: var(--bg-white);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            display: flex;
            flex-wrap: wrap;
            gap: var(--spacing-sm);
            justify-content: center;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
        }
        
        .nav-btn {
            background: var(--bg-light);
            border: 2px solid #e2e8f0;
            color: var(--text-primary);
            padding: 16px 24px;
            border-radius: 50px;
            cursor: pointer;
            font-size: 14px;
            font-weight: 600;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .nav-btn:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
            border-color: var(--primary-color);
        }
        
        .nav-btn.active {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            border-color: var(--primary-color);
            box-shadow: var(--shadow-md);
        }
        
        /* Content sections */
        .content-section {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
            display: none;
        }
        
        .content-section.active {
            display: block;
            animation: slideInUp 0.6s cubic-bezier(0.4, 0, 0.2, 1);
        }
        
        @keyframes slideInUp {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .section-title {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: var(--spacing-lg);
            position: relative;
            padding-bottom: var(--spacing-sm);
        }
        
        .section-title::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 4px;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            border-radius: 2px;
            animation: expandWidth 0.8s ease-out 0.3s both;
        }
        
        @keyframes expandWidth {
            from { width: 0; }
            to { width: 60px; }
        }
        
        /* Subsections */
        .subsection {
            margin-bottom: var(--spacing-lg);
            padding: var(--spacing-lg);
            background: var(--bg-light);
            border-radius: var(--border-radius);
            border: 1px solid #e2e8f0;
            transition: all 0.3s ease;
        }
        
        .subsection:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
        }
        
        .subsection h3 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.5rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .subsection h3::before {
            content: '';
            width: 4px;
            height: 24px;
            background: linear-gradient(135deg, var(--primary-color), var(--accent-color));
            border-radius: 2px;
        }
        
        .subsection p {
            color: var(--text-secondary);
            margin-bottom: 1rem;
            line-height: 1.7;
        }
        
        .subsection ul {
            color: var(--text-secondary);
            padding-left: 1.5rem;
        }
        
        .subsection li {
            margin-bottom: 0.5rem;
        }
        
        /* Tables */
        .clinical-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin: var(--spacing-md) 0;
            background: var(--bg-white);
            border-radius: var(--border-radius);
            overflow: hidden;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
        }
        
        .clinical-table th {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            padding: var(--spacing-md);
            text-align: left;
            font-weight: 600;
            font-size: 0.95rem;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .clinical-table td {
            padding: var(--spacing-md);
            border-bottom: 1px solid #f1f5f9;
            transition: all 0.3s ease;
            color: var(--text-primary);
        }
        
        .clinical-table tbody tr:hover {
            background: #f8fafc;
        }
        
        .clinical-table tbody tr:last-child td {
            border-bottom: none;
        }
        
        /* Pathway diagrams */
        .pathway-diagram {
            background: var(--bg-white);
            border: 2px solid var(--primary-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .pathway-diagram h4 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
            text-align: center;
        }
        
        /* Enzyme boxes */
        .enzyme-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            padding: 12px 20px;
            margin: 6px;
            border-radius: 12px;
            font-weight: 600;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .enzyme-box:hover {
            transform: translateY(-2px) scale(1.05);
            box-shadow: var(--shadow-md);
        }
        
        .enzyme-box.defect {
            background: linear-gradient(135deg, var(--danger-color), #dc2626);
            animation: pulseGlow 2s infinite;
        }
        
        @keyframes pulseGlow {
            0%, 100% {
                transform: scale(1);
                box-shadow: var(--shadow-sm);
            }
            50% {
                transform: scale(1.02);
                box-shadow: var(--shadow-md);
            }
        }
        
        .arrow {
            display: inline-block;
            margin: 0 var(--spacing-sm);
            font-size: 1.8rem;
            color: var(--primary-color);
            transition: all 0.3s ease;
        }
        
        .arrow:hover {
            transform: scale(1.2);
            color: var(--accent-color);
        }
        
        /* Highlight boxes */
        .highlight-box {
            background: linear-gradient(135deg, #fef3c7, #fde68a);
            border: 2px solid var(--warning-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            position: relative;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box::before {
            content: '‚ö†Ô∏è';
            position: absolute;
            top: -12px;
            left: 24px;
            background: linear-gradient(135deg, var(--warning-color), #fbbf24);
            padding: 8px 12px;
            border-radius: 50%;
            font-size: 1.2rem;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box h4 {
            color: #92400e;
            margin-bottom: var(--spacing-sm);
            margin-top: var(--spacing-sm);
            font-weight: 600;
        }
        
        .highlight-box p, .highlight-box ul, .highlight-box li {
            color: #92400e;
        }
        
        /* Case study boxes */
        .case-study {
            background: linear-gradient(135deg, #ecfdf5, #d1fae5);
            border: 2px solid var(--success-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .case-study h4 {
            color: #065f46;
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .case-study p, .case-study ul, .case-study li {
            color: #065f46;
        }
        
        /* Metabolite boxes */
        .metabolite-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--accent-color), #0ea5e9);
            color: white;
            padding: 10px 16px;
            margin: 4px;
            border-radius: 8px;
            font-size: 0.9rem;
            font-weight: 500;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .metabolite-box:hover {
            transform: translateY(-2px) scale(1.05);
            box-shadow: var(--shadow-md);
        }
        
        /* Hormone boxes for CAH */
        .hormone-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--secondary-color), #be185d);
            color: white;
            padding: 10px 16px;
            margin: 4px;
            border-radius: 8px;
            font-size: 0.9rem;
            font-weight: 500;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .hormone-box.elevated {
            background: linear-gradient(135deg, var(--danger-color), #dc2626);
            animation: pulseGlow 2s infinite;
        }
        
        .hormone-box.decreased {
            background: linear-gradient(135deg, #6b7280, #4b5563);
        }
        
        /* Buttons */
        .next-step {
            text-align: center;
            margin-top: var(--spacing-xl);
        }
        
        .next-btn {
            background: linear-gradient(135deg, var(--success-color), var(--accent-color));
            color: white;
            border: none;
            padding: 18px 36px;
            border-radius: 50px;
            cursor: pointer;
            font-size: 16px;
            font-weight: 600;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            box-shadow: var(--shadow-md);
            text-transform: uppercase;
            letter-spacing: 1px;
        }
        
        .next-btn:hover {
            transform: translateY(-4px) scale(1.05);
            box-shadow: var(--shadow-lg);
        }
        
        .part-info {
            background: linear-gradient(135deg, #eff6ff, #dbeafe);
            border: 2px solid var(--info-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-sm);
        }
        
        .part-info h3 {
            color: var(--info-color);
            margin-bottom: var(--spacing-sm);
        }
        
        .part-info p {
            color: var(--text-secondary);
        }
        
        /* Special steroid pathway styling */
        .steroid-pathway {
            background: linear-gradient(135deg, #fdf4ff, #fae8ff);
            border: 2px solid var(--primary-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        /* Responsive design */
        @media (max-width: 768px) {
            .container {
                padding: var(--spacing-sm);
            }
            
            .header h1 {
                font-size: 2.5rem;
            }
            
            .navigation {
                flex-direction: column;
            }
            
            .nav-btn {
                width: 100%;
                text-align: center;
            }
            
            .content-section {
                padding: var(--spacing-md);
            }
            
            .section-title {
                font-size: 2rem;
            }
        }
        
        /* Animation stagger */
        .subsection {
            animation: fadeInStagger 0.6s ease-out both;
        }
        
        @keyframes fadeInStagger {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .subsection:nth-child(1) { animation-delay: 0.1s; }
        .subsection:nth-child(2) { animation-delay: 0.2s; }
        .subsection:nth-child(3) { animation-delay: 0.3s; }
        .subsection:nth-child(4) { animation-delay: 0.4s; }
        .subsection:nth-child(5) { animation-delay: 0.5s; }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>üß¨ Cholesterin-/Steroid-Biosynthese</h1>
            <p>Teil 2B: Andere CAH-Formen & Erweiterte St√∂rungen</p>
            <div class="progress-container">
                <div class="progress-fill" id="progressBar" style="width: 0%"></div>
            </div>
        </div>

        <div class="part-info">
            <h3>üìö Lerneinheit Teil 2B</h3>
            <p>Dieser Teil behandelt die seltenen CAH-Formen (11Œ≤-Hydroxylase, 17Œ±-Hydroxylase, 3Œ≤-HSD2, StAR) und erweiterte Steroidogenese-St√∂rungen (PORD, Aldosteron-Synthase).</p>
        </div>

        <div class="navigation">
            <button class="nav-btn active" onclick="showSection('cah11b')">1. 11Œ≤-Hydroxylase</button>
            <button class="nav-btn" onclick="showSection('cah17a')">2. 17Œ±-Hydroxylase</button>
            <button class="nav-btn" onclick="showSection('cah-selten')">3. Seltene CAH</button>
            <button class="nav-btn" onclick="showSection('erweitert')">4. Erweiterte St√∂rungen</button>
        </div>

        <!-- 11Œ≤-Hydroxylase CAH -->
        <div class="content-section active" id="cah11b">
            <h2 class="section-title">üî• 11Œ≤-Hydroxylase-Mangel</h2>

            <div class="subsection">
                <h3>Epidemiologie und Pathophysiologie</h3>
                <div class="case-study">
                    <h4>üî¨ Zweith√§ufigste klassische CAH-Form</h4>
                    <p><strong>Epidemiologie:</strong></p>
                    <ul>
                        <li><strong>Inzidenz:</strong> 1:100.000 - 1:200.000 (5-8% aller CAH)</li>
                        <li><strong>Ethnische H√§ufung:</strong> J√ºdische Population aus Marokko (1:5.000)</li>
                        <li><strong>Gen:</strong> CYP11B1 (8q21-22)</li>
                        <li><strong>Vererbung:</strong> Autosomal-rezessiv</li>
                    </ul>
                </div>

                <div class="steroid-pathway">
                    <h4>CYP11B1-Defekt und Konsequenzen</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
                        <div style="display: flex; flex-direction: column; align-items: center; gap: 15px;">
                            <div class="metabolite-box">11-Deoxykortisol</div>
                            <span class="arrow" style="transform: rotate(90deg); color: #8b5cf6;">‚Üì</span>
                            
                            <div class="enzyme-box defect" style="font-size: 1.1em; padding: 15px 25px;">CYP11B1 (DEFEKT)</div>
                            <div style="text-align: center; color: #ef4444; font-weight: 600;">11Œ≤-Hydroxylase</div>
                            
                            <span class="arrow" style="transform: rotate(90deg); color: #8b5cf6;">‚Üì</span>
                            <div class="hormone-box decreased">Kortisol ‚Üì‚Üì</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; width: 100%; margin-top: 20px;">
                            <div style="text-align: center; padding: 15px; background: linear-gradient(135deg, #fef2f2, #fecaca); border-radius: 8px; border: 2px solid #ef4444;">
                                <h5 style="color: #dc2626; margin-bottom: 10px;">‚Üë Akkumulation</h5>
                                <div class="hormone-box elevated">11-Deoxykortisol ‚Üë‚Üë</div>
                                <div class="hormone-box elevated">11-Deoxykortikosteron (DOC) ‚Üë‚Üë</div>
                                <div class="hormone-box elevated">Androgene ‚Üë‚Üë</div>
                            </div>
                            <div style="text-align: center; padding: 15px; background: linear-gradient(135deg, #f0fdf4, #dcfce7); border-radius: 8px; border: 2px solid #22c55e;">
                                <h5 style="color: #16a34a; margin-bottom: 10px;">Klinische Folgen</h5>
                                <p style="color: #16a34a; font-size: 0.9em;">‚Ä¢ <strong>Hypertonie</strong> (DOC!)<br>‚Ä¢ <strong>Hypokali√§mie</strong><br>‚Ä¢ <strong>Virilisierung</strong><br>‚Ä¢ <strong>Kein Salzverlust</strong></p>
                            </div>
                        </div>
                    </div>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Parameter</th>
                            <th>21-Hydroxylase CAH</th>
                            <th>11Œ≤-Hydroxylase CAH</th>
                            <th>Klinische Bedeutung</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Hauptmarker</strong></td>
                            <td>17-OH-Progesteron ‚Üë‚Üë</td>
                            <td>11-Deoxykortisol ‚Üë‚Üë</td>
                            <td>Spezifische Biomarker</td>
                        </tr>
                        <tr>
                            <td><strong>Mineralokortikoid</strong></td>
                            <td>Aldosteron ‚Üì (Salzverlust)</td>
                            <td>DOC ‚Üë (Hypertonie)</td>
                            <td>Gegens√§tzliche Effekte</td>
                        </tr>
                        <tr>
                            <td><strong>Virilisierung</strong></td>
                            <td>Ja</td>
                            <td>Ja (oft st√§rker)</td>
                            <td>Beide betroffen</td>
                        </tr>
                        <tr>
                            <td><strong>Besonderheit</strong></td>
                            <td>Salzverlust m√∂glich</td>
                            <td>Hypertonie charakteristisch</td>
                            <td>Unterscheidungsmerkmal</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Diagnostik und Therapie</h3>
                <div class="highlight-box">
                    <h4>Diagnostische Besonderheiten</h4>
                    <p><strong>Labordiagnostik:</strong></p>
                    <ul>
                        <li><strong>Prim√§rmarker:</strong> 11-Deoxykortisol >20 Œºg/dl (Normal: <1 Œºg/dl)</li>
                        <li><strong>ACTH-Test:</strong> 11-Deoxykortisol steigt >50 Œºg/dl</li>
                        <li><strong>DOC erh√∂ht:</strong> Ursache der Hypertonie und Hypokali√§mie</li>
                        <li><strong>17-OHP:</strong> Kann m√§√üig erh√∂ht sein (DD zu 21-OHD)</li>
                    </ul>
                    
                    <p><strong>H√§ufige Mutationen:</strong></p>
                    <ul>
                        <li><strong>R448H:</strong> H√§ufigste Mutation weltweit (30%)</li>
                        <li><strong>Q356X:</strong> Nonsense-Mutation (20%)</li>
                        <li><strong>R374W:</strong> Missense mit residualer Aktivit√§t (15%)</li>
                        <li><strong>L299P:</strong> Founder-Mutation bei marokkanischen Juden</li>
                    </ul>
                </div>

                <div class="case-study">
                    <h4>üíä Therapieprotokoll</h4>
                    <p><strong>Glukokortikoid-Substitution:</strong></p>
                    <ul>
                        <li><strong>Hydrocortison:</strong> Wie bei 21-OHD (10-15 mg/m¬≤/d)</li>
                        <li><strong>Monitoring:</strong> 11-Deoxykortisol als Verlaufsparameter</li>
                        <li><strong>Zielwerte:</strong> 11-Deoxykortisol <10 Œºg/dl</li>
                    </ul>
                    
                    <p><strong>Antihypertensive Therapie:</strong></p>
                    <ul>
                        <li><strong>Spironolacton:</strong> 1-3 mg/kg/d (DOC-Antagonist)</li>
                        <li><strong>ACE-Hemmer:</strong> Bei unzureichender Kontrolle</li>
                        <li><strong>Kalziumkanalblocker:</strong> Alternative bei Jugendlichen</li>
                        <li><strong>KEIN Fludrocortison:</strong> Kontraindiziert wegen DOC-Exzess</li>
                    </ul>
                    
                    <p><strong>Besondere √úberwachung:</strong></p>
                    <ul>
                        <li><strong>Blutdruck:</strong> Regelm√§√üig, 24h-RR bei Verdacht</li>
                        <li><strong>Kalium:</strong> Engmaschig, Substitution oft n√∂tig</li>
                        <li><strong>Echokardiographie:</strong> Bei Hypertonie-Nachweis</li>
                        <li><strong>Nierenfunktion:</strong> Langzeitfolgen der Hypertonie</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('cah17a')">Weiter zu 17Œ±-Hydroxylase ‚Üí</button>
            </div>
        </div>

        <!-- 17Œ±-Hydroxylase CAH -->
        <div class="content-section" id="cah17a">
            <h2 class="section-title">üåü 17Œ±-Hydroxylase/17,20-Lyase-Mangel</h2>

            <div class="subsection">
                <h3>Dualer Enzymdefekt</h3>
                <div class="steroid-pathway">
                    <h4>CYP17A1 - Zwei enzymatische Aktivit√§ten</h4>
                    
                    <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 20px 0;">
                        <div>
                            <p style="color: #7c3aed; font-weight: 600; margin-bottom: 10px;">17Œ±-Hydroxylase Aktivit√§t:</p>
                            <div style="font-size: 0.9em; color: #7c3aed;">
                                <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed); margin: 5px 0;">Pregnenolon ‚Üí 17-OH-Pregnenolon</div>
                                <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed); margin: 5px 0;">Progesteron ‚Üí 17-OH-Progesteron</div>
                            </div>
                        </div>
                        <div>
                            <p style="color: #7c3aed; font-weight: 600; margin-bottom: 10px;">17,20-Lyase Aktivit√§t:</p>
                            <div style="font-size: 0.9em; color: #7c3aed;">
                                <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed); margin: 5px 0;">17-OH-Pregnenolon ‚Üí DHEA</div>
                                <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed); margin: 5px 0;">17-OH-Progesteron ‚Üí Androstendion</div>
                            </div>
                        </div>
                    </div>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Hormonsystem</th>
                            <th>Betroffene Hormone</th>
                            <th>Laborwerte</th>
                            <th>Klinische Manifestation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Glukokortikoide</strong></td>
                            <td>Kortisol ‚Üì</td>
                            <td>Kortisol <5 Œºg/dl</td>
                            <td>Meist asymptomatisch (genug DOC)</td>
                        </tr>
                        <tr>
                            <td><strong>Mineralokortkoide</strong></td>
                            <td>DOC ‚Üë, Aldosteron ‚Üì</td>
                            <td>DOC >5 ng/ml</td>
                            <td>Hypertonie, Hypokali√§mie</td>
                        </tr>
                        <tr>
                            <td><strong>Sexualhormone</strong></td>
                            <td>Alle Androgene/√ñstrogene ‚Üì</td>
                            <td>Testosteron <50 ng/dl</td>
                            <td>Sexueller Infantilismus</td>
                        </tr>
                        <tr>
                            <td><strong>Biomarker</strong></td>
                            <td>17-OH-Steroide ‚Üì</td>
                            <td>17-OHP <30 ng/ml</td>
                            <td>Diagnostischer Marker</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Klinisches Spektrum</h3>
                <div class="case-study">
                    <h4>üë§ Geschlechtsspezifische Manifestationen</h4>
                    <p><strong>46,XX Patienten:</strong></p>
                    <ul>
                        <li><strong>√Ñu√üere Genitalien:</strong> Normal weiblich (keine Androgenexposition)</li>
                        <li><strong>Pubert√§t:</strong> Ausbleibende Menarche, fehlende Brustentwicklung</li>
                        <li><strong>Gonaden:</strong> Streak ovaries, keine √ñstrogen-Produktion</li>
                        <li><strong>Gr√∂√üe:</strong> Oft √ºberdurchschnittlich (fehlende √ñstrogeneffekte)</li>
                    </ul>
                    
                    <p><strong>46,XY Patienten:</strong></p>
                    <ul>
                        <li><strong>Genitalien:</strong> Weibliches Erscheinungsbild (komplette Androgenresistenz-√§hnlich)</li>
                        <li><strong>Interne Strukturen:</strong> Hoden vorhanden, oft intraabdominal</li>
                        <li><strong>Geschlechtsidentit√§t:</strong> Meist weiblich (durch Erziehung)</li>
                        <li><strong>Tumor-Risiko:</strong> Gonadoblastom-Risiko bei Streak gonads</li>
                    </ul>
                </div>

                <div class="highlight-box">
                    <h4>Besondere klinische Merkmale</h4>
                    <p><strong>Beide Geschlechter:</strong></p>
                    <ul>
                        <li><strong>Hypertonie:</strong> Durch DOC-Exzess (90% der Patienten)</li>
                        <li><strong>Hypokali√§mie:</strong> Oft schwer (<3 mmol/l)</li>
                        <li><strong>Osteoporose:</strong> Durch Hypogonadismus</li>
                        <li><strong>Metabolisches Syndrom:</strong> Durch Kortisolmangel</li>
                    </ul>
                    
                    <p><strong>Diagnostische Hinweise:</strong></p>
                    <ul>
                        <li><strong>17-OH-Steroide ‚Üì:</strong> Im Gegensatz zu anderen CAH-Formen</li>
                        <li><strong>DOC/Kortikosteron ‚Üë:</strong> Spezifischer Marker</li>
                        <li><strong>Progesteron ‚Üë:</strong> Akkumulation proximal des Blocks</li>
                        <li><strong>ACTH ‚Üë:</strong> Kompensatorisch erh√∂ht</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Therapie und Management</h3>
                <div class="case-study">
                    <h4>üíä Multimodales Behandlungskonzept</h4>
                    <p><strong>Hormonsubstitution:</strong></p>
                    <ul>
                        <li><strong>Hydrocortison:</strong> 10-15 mg/m¬≤/d (Kortisolersatz)</li>
                        <li><strong>Sexualhormone:</strong> Ab Pubert√§tsalter essentiell</li>
                        <li><strong>46,XX:</strong> √ñstrogen + Gestagen (normale weibliche Entwicklung)</li>
                        <li><strong>46,XY:</strong> Testosteron ODER √ñstrogen (je nach Geschlechtsidentit√§t)</li>
                    </ul>
                    
                    <p><strong>Hypertonie-Management:</strong></p>
                    <ul>
                        <li><strong>Spironolacton:</strong> Erstlinien-Therapie (DOC-Antagonist)</li>
                        <li><strong>Thiazid-Diuretika:</strong> Bei unzureichender Kontrolle</li>
                        <li><strong>ACE-Hemmer:</strong> Zus√§tzliche Nephro- und Kardioprotektion</li>
                        <li><strong>Kalium-Substitution:</strong> Oft dauerhaft erforderlich</li>
                    </ul>
                    
                    <p><strong>Besondere √úberlegungen:</strong></p>
                    <ul>
                        <li><strong>Gonadektomie:</strong> Bei 46,XY mit weiblicher Identit√§t (Tumor-Risiko)</li>
                        <li><strong>Familienplanung:</strong> Adoption oder Eizell-/Samenspende</li>
                        <li><strong>Psychologische Betreuung:</strong> DSD-Team unerl√§sslich</li>
                        <li><strong>Osteoporose-Prophylaxe:</strong> Kalzium, Vitamin D, Bisphosphonate</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('cah-selten')">Weiter zu seltenen CAH ‚Üí</button>
            </div>
        </div>

        <!-- Seltene CAH-Formen -->
        <div class="content-section" id="cah-selten">
            <h2 class="section-title">üß¨ Seltene CAH-Formen</h2>

            <div class="subsection">
                <h3>3Œ≤-Hydroxysteroid-Dehydrogenase Typ 2 Mangel</h3>
                <div class="steroid-pathway">
                    <h4>HSD3B2-Defekt</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
                        <div style="background: #fee2e2; padding: 20px; border-radius: 10px; width: 100%; border: 2px solid #ef4444;">
                            <div style="text-align: center;">
                                <h5 style="color: #dc2626; margin-bottom: 15px;">3Œ≤-HSD2 = Œî5‚ÜíŒî4 Konversion</h5>
                                <p style="color: #dc2626; margin-bottom: 10px;"><strong>Funktion:</strong> Œî5-Steroide ‚Üí Œî4-Steroide + 3-Keto-Reduktion</p>
                                <p style="color: #dc2626;"><strong>Lokalisation:</strong> Nebenniere, Gonaden, Plazenta</p>
                            </div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; width: 100%;">
                            <div style="text-align: center; padding: 15px; background: linear-gradient(135deg, #fef2f2, #fecaca); border-radius: 8px; border: 2px solid #ef4444;">
                                <h5 style="color: #dc2626; margin-bottom: 10px;">‚Üë Œî5-Steroide</h5>
                                <div class="hormone-box elevated">Pregnenolon ‚Üë‚Üë</div>
                                <div class="hormone-box elevated">17-OH-Pregnenolon ‚Üë‚Üë</div>
                                <div class="hormone-box elevated">DHEA ‚Üë‚Üë</div>
                            </div>
                            <div style="text-align: center; padding: 15px; background: linear-gradient(135deg, #f0fdf4, #dcfce7); border-radius: 8px; border: 2px solid #22c55e;">
                                <h5 style="color: #16a34a; margin-bottom: 10px;">‚Üì Œî4-Steroide</h5>
                                <div class="hormone-box decreased">Progesteron ‚Üì‚Üì</div>
                                <div class="hormone-box decreased">17-OHP ‚Üì‚Üì</div>
                                <div class="hormone-box decreased">Androstendion ‚Üì‚Üì</div>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="case-study">
                    <h4>üîç Diagnostische Besonderheiten</h4>
                    <p><strong>Biochemische Charakteristika:</strong></p>
                    <ul>
                        <li><strong>Œî5/Œî4-Steroid Ratio >5:</strong> Pathognomonisch</li>
                        <li><strong>17-OH-Pregnenolon/17-OHP >10:</strong> Spezifischer Marker</li>
                        <li><strong>DHEA-S massiv erh√∂ht:</strong> Oft >10.000 Œºg/dl</li>
                        <li><strong>Schwacher Androgen:</strong> DHEA wenig virilisierend</li>
                    </ul>
                    
                    <p><strong>Klinische Manifestation:</strong></p>
                    <ul>
                        <li><strong>Salzverlust:</strong> Meist schwer (fehlende Mineralokortkoide)</li>
                        <li><strong>Milde Virilisierung:</strong> Weniger als bei 21-OHD</li>
                        <li><strong>46,XY Patienten:</strong> Oft undervirilized, Mikropenis</li>
                        <li><strong>Prognose:</strong> Schlecht bei schweren Formen</li>
                    </ul>
                    
                    <p><strong>Molekulargenetik:</strong></p>
                    <ul>
                        <li><strong>HSD3B2-Gen:</strong> 1p12, 4 Exons</li>
                        <li><strong>H√§ufige Mutationen:</strong> A82T, P222Q, G129R</li>
                        <li><strong>Typ I vs. Typ II:</strong> Typ II (adrenal/gonadal) betroffen</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>StAR-Protein Defekt (Lipoid CAH)</h3>
                <div class="steroid-pathway">
                    <h4>Schwerstes CAH-Syndrom</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
                        <div style="background: #fee2e2; padding: 20px; border-radius: 10px; width: 100%; border: 2px solid #ef4444;">
                            <div style="text-align: center;">
                                <h5 style="color: #dc2626; margin-bottom: 15px;">StAR = Steroidogenic Acute Regulatory Protein</h5>
                                <p style="color: #dc2626; margin-bottom: 10px;"><strong>Funktion:</strong> Cholesterin-Transport in Mitochondrien</p>
                                <p style="color: #dc2626;"><strong>Bedeutung:</strong> Rate-limiting step der Steroidogenese</p>
                            </div>
                        </div>
                        
                        <div style="display: flex; flex-direction: column; align-items: center; gap: 15px;">
                            <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed);">Cholesterin (Cytoplasma)</div>
                            <span class="arrow" style="transform: rotate(90deg); color: #ef4444;">‚ùå</span>
                            
                            <div class="enzyme-box defect" style="font-size: 1.1em; padding: 15px 25px;">StAR-Protein (DEFEKT)</div>
                            <div style="text-align: center; color: #ef4444; font-weight: 600;">Cholesterin-Transport blockiert</div>
                            
                            <span class="arrow" style="transform: rotate(90deg); color: #ef4444;">‚ùå</span>
                            <div class="metabolite-box" style="background: linear-gradient(135deg, #6b7280, #4b5563);">Cholesterin (Mitochondrien)</div>
                            
                            <div style="margin-top: 20px; text-align: center; background: #fef2f2; padding: 15px; border-radius: 8px; border: 2px solid #ef4444;">
                                <h5 style="color: #dc2626; margin-bottom: 10px;">Konsequenz: Kompletter Steroidmangel</h5>
                                <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(120px, 1fr)); gap: 10px;">
                                    <div class="hormone-box decreased">Kortisol ‚Üì‚Üì</div>
                                    <div class="hormone-box decreased">Aldosteron ‚Üì‚Üì</div>
                                    <div class="hormone-box decreased">Testosteron ‚Üì‚Üì</div>
                                    <div class="hormone-box decreased">√ñstrogen ‚Üì‚Üì</div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="highlight-box">
                    <h4>Klinische Charakteristika</h4>
                    <p><strong>Schwere neonatale Manifestation:</strong></p>
                    <ul>
                        <li><strong>Salzverlustkrise:</strong> Innerhalb weniger Tage, oft letal</li>
                        <li><strong>Adrenale Insuffizienz:</strong> Komplette Steroidproduktion ‚Üì</li>
                        <li><strong>46,XY DSD:</strong> Komplett weibliches Erscheinungsbild</li>
                        <li><strong>Lipid-Akkumulation:</strong> In Nebennieren und Gonaden ("lipoid")</li>
                    </ul>
                    
                    <p><strong>Diagnostik:</strong></p>
                    <ul>
                        <li><strong>Alle Steroide ‚Üì:</strong> Kortisol, Aldosteron, Sexualhormone</li>
                        <li><strong>ACTH-Test:</strong> Kein Anstieg von Steroiden</li>
                        <li><strong>Molekulargenetik:</strong> STAR-Gen Mutationen</li>
                        <li><strong>Bildgebung:</strong> Vergr√∂√üerte, "lipoid" Nebennieren</li>
                    </ul>
                    
                    <p><strong>Prognose und Therapie:</strong></p>
                    <ul>
                        <li><strong>Mortalit√§t:</strong> Hoch ohne fr√ºhzeitige Diagnose</li>
                        <li><strong>Substitution:</strong> Hydrocortison + Fludrocortison</li>
                        <li><strong>Pubert√§t:</strong> Sexualhormon-Substitution erforderlich</li>
                        <li><strong>Lebenserwartung:</strong> Normal bei ad√§quater Therapie</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('erweitert')">Weiter zu erweiterten St√∂rungen ‚Üí</button>
            </div>
        </div>

        <!-- Erweiterte St√∂rungen -->
        <div class="content-section" id="erweitert">
            <h2 class="section-title">üî¨ Erweiterte Steroidogenese-St√∂rungen</h2>

            <div class="subsection">
                <h3>P450-Oxidoreduktase-Defekt (PORD)</h3>
                <div class="steroid-pathway">
                    <h4>Elektron-Transfer-St√∂rung</h4>
                    
                    <div style="background: linear-gradient(135deg, #f0f9ff, #e0f2fe); padding: 20px; border-radius: 10px; margin: 20px 0; border: 2px solid #0891b2;">
                        <div style="text-align: center; margin-bottom: 20px;">
                            <h5 style="color: #0891b2; margin-bottom: 15px;">P450-Oxidoreduktase (POR) - Universeller Elektronendonor</h5>
                            <p style="color: #0891b2; margin-bottom: 10px;"><strong>Funktion:</strong> NADPH ‚Üí Cytochrom P450 Enzyme</p>
                            <p style="color: #0891b2;"><strong>Betroffene Enzyme:</strong> CYP17A1, CYP21A2, CYP19A1 (Aromatase)</p>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px;">
                            <div>
                                <p style="color: #0891b2; font-weight: 600; margin-bottom: 10px;">Betroffene Pathways:</p>
                                <ul style="font-size: 0.9em; color: #0891b2;">
                                    <li>Kortisol-Synthese ‚Üì (17Œ±-Hydroxylase)</li>
                                    <li>Androgen-Synthese ‚Üì (17,20-Lyase)</li>
                                    <li>√ñstrogen-Synthese ‚Üì (Aromatase)</li>
                                    <li>Medikamenten-Metabolismus ‚Üì</li>
                                </ul>
                            </div>
                            <div>
                                <p style="color: #0891b2; font-weight: 600; margin-bottom: 10px;">Zus√§tzliche Merkmale:</p>
                                <ul style="font-size: 0.9em; color: #0891b2;">
                                    <li>Skelettale Malformationen</li>
                                    <li>Antley-Bixler Syndrom</li>
                                    <li>Maternale Virilisierung</li>
                                    <li>Drug metabolism defects</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Schweregrad</th>
                            <th>Enzymaktivit√§t</th>
                            <th>Skelettale Beteiligung</th>
                            <th>Endokrine St√∂rung</th>
                            <th>Prognose</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Schwer</strong></td>
                            <td><5%</td>
                            <td>Antley-Bixler Syndrom</td>
                            <td>Schwere Steroidmangel</td>
                            <td>Oft letal</td>
                        </tr>
                        <tr>
                            <td><strong>Moderat</strong></td>
                            <td>5-20%</td>
                            <td>Milde Dysmorphie</td>
                            <td>Ambige Genitalien</td>
                            <td>Gut mit Therapie</td>
                        </tr>
                        <tr>
                            <td><strong>Mild</strong></td>
                            <td>20-50%</td>
                            <td>Keine/minimal</td>
                            <td>Reproduktive Probleme</td>
                            <td>Normal</td>
                        </tr>
                    </tbody>
                </table>

                <div class="case-study">
                    <h4>üèóÔ∏è Antley-Bixler Syndrom</h4>
                    <p><strong>Skelettale Malformationen:</strong></p>
                    <ul>
                        <li><strong>Craniosynostose:</strong> Multiple N√§hte betroffen</li>
                        <li><strong>Faziale Dysmorphie:</strong> Hypertelorismus, flache Nasenwurzel</li>
                        <li><strong>Extremit√§ten:</strong> Radiohumeral Synostose, Bowing fractures</li>
                        <li><strong>Wirbels√§ule:</strong> Scoliose, vertebrale Malformationen</li>
                    </ul>
                    
                    <p><strong>Endokrine Manifestationen:</strong></p>
                    <ul>
                        <li><strong>46,XY DSD:</strong> Undervirilization bis weibliches Erscheinungsbild</li>
                        <li><strong>Maternale Virilisierung:</strong> W√§hrend Schwangerschaft</li>
                        <li><strong>Adrenale Insuffizienz:</strong> Meist mild</li>
                        <li><strong>Pubert√§tsst√∂rungen:</strong> Verz√∂gert oder ausbleibend</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Aldosteron-Synthase-Defekt (CYP11B2)</h3>
                <div class="highlight-box">
                    <h4>Isolierte Mineralokortikoid-Insuffizienz</h4>
                    <p><strong>Corticosterone Methyloxidase Deficiency:</strong></p>
                    <ul>
                        <li><strong>Typ I (CMO-I):</strong> 18-Hydroxylase-Defekt</li>
                        <li><strong>Typ II (CMO-II):</strong> 18-Oxidase-Defekt</li>
                        <li><strong>Beide:</strong> F√ºhren zu Aldosteron-Mangel</li>
                    </ul>
                    
                    <p><strong>Klinische Merkmale:</strong></p>
                    <ul>
                        <li><strong>Salzverlust:</strong> Ohne Kortisol-Mangel</li>
                        <li><strong>Hyperrenin√§mie:</strong> Kompensatorisch</li>
                        <li><strong>Normale Virilisierung:</strong> Androgene nicht betroffen</li>
                        <li><strong>Therapie:</strong> Nur Fludrocortison erforderlich</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Aromatase-Defekt (CYP19A1)</h3>
                <div class="case-study">
                    <h4>üß¨ St√∂rung der √ñstrogen-Synthese</h4>
                    <p><strong>Pathophysiologie:</strong></p>
                    <ul>
                        <li><strong>Enzym:</strong> Aromatase (CYP19A1)</li>
                        <li><strong>Funktion:</strong> Androstendion ‚Üí √ñstron, Testosteron ‚Üí √ñstradiol</li>
                        <li><strong>Lokalisation:</strong> Ovarien, Testes, Knochen, Fettgewebe</li>
                    </ul>
                    
                    <p><strong>Klinische Manifestationen:</strong></p>
                    <ul>
                        <li><strong>46,XX:</strong> Virilisierung durch Androgen-Akkumulation</li>
                        <li><strong>46,XY:</strong> Hochwuchs, verz√∂gerter Epiphysenschluss</li>
                        <li><strong>Maternale Virilisierung:</strong> W√§hrend Schwangerschaft</li>
                        <li><strong>Osteoporose:</strong> Durch √ñstrogen-Mangel</li>
                    </ul>
                    
                    <p><strong>Diagnostik und Therapie:</strong></p>
                    <ul>
                        <li><strong>Androstendion/√ñstron ‚Üë:</strong> Charakteristisches Verh√§ltnis</li>
                        <li><strong>√ñstradiol ‚Üì:</strong> Trotz hoher Testosteron-Werte</li>
                        <li><strong>Therapie:</strong> √ñstrogen-Substitution</li>
                        <li><strong>Fertilit√§t:</strong> Meist erhalten</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>5Œ±-Reduktase Typ 2 Defekt</h3>
                <div class="steroid-pathway">
                    <h4>Dihydrotestosteron-Mangel</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
                        <div style="background: #f8fafc; padding: 15px; border-radius: 8px; text-align: center; width: 100%;">
                            <h5 style="color: #8b5cf6; margin-bottom: 10px;">5Œ±-Reduktase Typ 2 (SRD5A2)</h5>
                            <p style="font-size: 0.9em; color: #6b7280;">Testosteron ‚Üí Dihydrotestosteron (DHT)</p>
                        </div>
                        
                        <div style="display: flex; align-items: center; gap: 15px; flex-wrap: wrap; justify-content: center;">
                            <div class="metabolite-box">Testosteron</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box defect">5Œ±-Reduktase Typ 2</div>
                            <span class="arrow">‚Üí</span>
                            <div class="hormone-box decreased">DHT ‚Üì‚Üì</div>
                        </div>
                    </div>
                </div>

                <div class="case-study">
                    <h4>üîç 46,XY DSD durch DHT-Mangel</h4>
                    <p><strong>Klinische Charakteristika:</strong></p>
                    <ul>
                        <li><strong>Geburt:</strong> Weibliches oder ambiges Erscheinungsbild</li>
                        <li><strong>Pubert√§t:</strong> Maskulinisierung durch Testosteron-Anstieg</li>
                        <li><strong>Interne Strukturen:</strong> Normal m√§nnlich (Wolff-Dukte)</li>
                        <li><strong>Prostatahypoplasie:</strong> DHT-abh√§ngige Entwicklung gest√∂rt</li>
                    </ul>
                    
                    <p><strong>Diagnostik:</strong></p>
                    <ul>
                        <li><strong>Testosteron/DHT Ratio >20:</strong> Nach hCG-Stimulation</li>
                        <li><strong>Androstendion/Etiocholanolon >5:</strong> Urin-Steroide</li>
                        <li><strong>Molekulargenetik:</strong> SRD5A2-Gen Mutationen</li>
                    </ul>
                    
                    <p><strong>Management:</strong></p>
                    <ul>
                        <li><strong>Geschlechtszuordnung:</strong> Oft m√§nnlich nach Pubert√§t</li>
                        <li><strong>Chirurgie:</strong> Genitoplastik individuell</li>
                        <li><strong>DHT-Gel:</strong> Experimentelle Therapie</li>
                        <li><strong>Psychologische Betreuung:</strong> DSD-Team</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Zusammenfassung und Vergleich</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>St√∂rung</th>
                            <th>Inzidenz</th>
                            <th>Hauptmerkmal</th>
                            <th>Diagnostischer Marker</th>
                            <th>Therapie</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>21-OHD</strong></td>
                            <td>1:15.000</td>
                            <td>Virilisierung ¬± Salzverlust</td>
                            <td>17-OHP ‚Üë‚Üë</td>
                            <td>HC + FC</td>
                        </tr>
                        <tr>
                            <td><strong>11Œ≤-OHD</strong></td>
                            <td>1:100.000</td>
                            <td>Virilisierung + Hypertonie</td>
                            <td>11-Deoxykortisol ‚Üë‚Üë</td>
                            <td>HC + Antihypertensiva</td>
                        </tr>
                        <tr>
                            <td><strong>17Œ±-OHD</strong></td>
                            <td>1:1.000.000</td>
                            <td>Hypertonie + Hypogonadismus</td>
                            <td>17-OH-Steroide ‚Üì</td>
                            <td>HC + Sexualhormone</td>
                        </tr>
                        <tr>
                            <td><strong>3Œ≤-HSD2</strong></td>
                            <td>1:1.000.000</td>
                            <td>Salzverlust + milde Virilisierung</td>
                            <td>Œî5/Œî4-Ratio >5</td>
                            <td>HC + FC</td>
                        </tr>
                        <tr>
                            <td><strong>StAR</strong></td>
                            <td>1:300.000</td>
                            <td>Kompletter Steroidmangel</td>
                            <td>Alle Steroide ‚Üì</td>
                            <td>HC + FC + Sexualhormone</td>
                        </tr>
                        <tr>
                            <td><strong>PORD</strong></td>
                            <td>1:300.000</td>
                            <td>Skelettale + endokrine St√∂rung</td>
                            <td>Complex steroid pattern</td>
                            <td>Symptomatisch</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="next-step">
                <div style="text-align: center; margin-top: 2rem; padding: 2rem; background: linear-gradient(135deg, #eff6ff, #dbeafe); border-radius: var(--border-radius); border: 2px solid var(--info-color);">
                    <h3 style="color: var(--info-color); margin-bottom: 1rem;">üéâ Teil 2B abgeschlossen!</h3>
                    <p style="color: var(--text-secondary); margin-bottom: 1.5rem;">Sie haben alle CAH-Formen und erweiterte Steroidogenese-St√∂rungen erfolgreich durchgearbeitet.</p>
                    <p style="color: var(--text-secondary); margin-bottom: 1.5rem;"><strong>Gesamtes Curriculum vollst√§ndig!</strong> Teil 1 (Grundlagen + SLOS), Teil 2A (Desmosterolosis + 21-OHD CAH), Teil 2B (Andere CAH + Erweiterte St√∂rungen)</p>
                    <div class="completion-badge" style="background: linear-gradient(135deg, var(--success-color), #00f2fe); color: white; padding: var(--spacing-md) var(--spacing-lg); border-radius: 50px; display: inline-block; font-weight: 600; margin: var(--spacing-md) 0; box-shadow: var(--shadow-md);">‚úÖ Lernziele erreicht!</div>
                </div>
            </div>
        </div>
    </div>

    <script>
        let currentSection = 0;
        const sections = ['cah11b', 'cah17a', 'cah-selten', 'erweitert'];

        function showSection(sectionId) {
            // Hide all sections
            const allSections = document.querySelectorAll('.content-section');
            allSections.forEach(section => section.classList.remove('active'));

            // Remove active class from all nav buttons
            const allButtons = document.querySelectorAll('.nav-btn');
            allButtons.forEach(btn => btn.classList.remove('active'));

            // Show selected section
            document.getElementById(sectionId).classList.add('active');

            // Highlight active nav button
            event.target.classList.add('active');

            // Update progress bar
            currentSection = sections.indexOf(sectionId);
            const progress = ((currentSection + 1) / sections.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';

            // Scroll to top
            window.scrollTo(0, 0);
        }

        // Initialize progress bar
        document.getElementById('progressBar').style.width = '25%';
    </script>
</body>
</html>